563. Phase II Trial of Belagenpumatucel-L, a TGF-β2 Antisense Gene Modified Allogeneic Tumor Vaccine in Advanced Non Small Cell Lung Cancer (NSCLC) Patients

Molecular Therapy ◽

10.1016/s1525-0016(16)38921-3 ◽

2009 ◽

Vol 17 ◽

pp. S215

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Tumor Vaccine ◽

Small Cell Lung ◽

Antisense Gene ◽

Download Full-text

Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients

Cancer Gene Therapy ◽

10.1038/cgt.2009.15 ◽

2009 ◽

Vol 16 (8) ◽

pp. 620-624 ◽

Author(s):

J Nemunaitis ◽

M Nemunaitis ◽

N Senzer ◽

P Snitz ◽

C Bedell ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Tumor Vaccine ◽

Small Cell Lung ◽

Antisense Gene ◽

Download Full-text

Abstract CT041: Identification of gene signatures associated with response in a Phase II trial of entinostat (ENT) plus pembrolizumab (PEMBRO) in non-small cell lung cancer (NSCLC) patients whose disease has progressed on or after anti-PD-(L)1 therapy

10.1158/1538-7445.am2019-ct041 ◽

2019 ◽

Author(s):

Peter Ordentlich ◽

Lei Wang ◽

David Tamang ◽

Amy H. Sullivan ◽

Sally E. Church ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell Lung ◽

Gene Signatures ◽

Download Full-text

Randomised Phase II Trial of Oral Vinorelbine (N) and Cisplatin (P) or Pemetrexed and C (PC) in First Line Advanced Non Squamous (NSCC) Non Small Cell Lung Cancer (NSCLC) Patients (PTS). Navotrial01: Final Results

Annals of Oncology ◽

10.1016/s0923-7534(20)33841-2 ◽

2012 ◽

Vol 23 ◽

pp. ix409

Author(s):

E.H. Tan ◽

L. Havel ◽

M.J. Krzakowski ◽

J. Kollmeier ◽

R. Gervais ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell Lung ◽

Oral Vinorelbine ◽

Download Full-text

Sequential vinorelbine (V) and docetaxel (D) in advanced non-small cell lung cancer (NSCLC) patients age > 70, or with performance status (PS) 2: A SWOG phase II trial (S0027)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.7056 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 7056-7056 ◽

Author(s):

P. J. Hesketh ◽

K. Chansky ◽

D. H. Lau ◽

J. Crowley ◽

D. R. Gandara

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Performance Status ◽

Small Cell Lung ◽

Download Full-text

P-203 SLCG 9901: phase II trial with cisplatin (cis), gemcitabine (gem) and docetaxel (doc) as neoadjuvant treatment in stage IIIA N2 and T4N0-1 non-small cell lung cancer (NSCLC) patients

Lung Cancer ◽

10.1016/s0169-5002(03)92172-6 ◽

2003 ◽

Vol 41 ◽

pp. S142

Author(s):

Pilar Garrido ◽

Ramón Barceló ◽

Angel Artal ◽

Josefa Terrasa ◽

Bartomeu Massuti ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Neoadjuvant Treatment ◽

Small Cell Lung ◽

Download Full-text

Abstract CT041: Identification of gene signatures associated with response in a Phase II trial of entinostat (ENT) plus pembrolizumab (PEMBRO) in non-small cell lung cancer (NSCLC) patients whose disease has progressed on or after anti-PD-(L)1 therapy

10.1158/1538-7445.sabcs18-ct041 ◽

2019 ◽

Author(s):

Peter Ordentlich ◽

Lei Wang ◽

David Tamang ◽

Amy H. Sullivan ◽

Sally E. Church ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell Lung ◽

Gene Signatures ◽

Download Full-text

O-033 Docetaxel (DOC), cisplatin (CIS) and gemcitabine (GEM) asneoadjuvant treatment in stage IIIAN2 and T4N0-1 non-small cell lung cancer (NSCLC) patients (P). final results of SLCG phase II trial 9901

Lung Cancer ◽

10.1016/s0169-5002(05)80165-5 ◽

2005 ◽

Vol 49 ◽

pp. S14 ◽

Author(s):

P. Garrido ◽

R. Rosell ◽

A. Torres ◽

J. González Larriba ◽

M. Provencio ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell Lung ◽

Download Full-text

P-533 Single agent weekly paclitaxel chemotherapy in elderly or frailnon-small cell lung cancer (NSCLC) patients: Final results of a phase II trial Spanish Lung Cancer Group (GECP 00/02)

Lung Cancer ◽

10.1016/s0169-5002(05)81026-8 ◽

2005 ◽

Vol 49 ◽

pp. S257-S258

Author(s):

B. Massuti ◽

C. Camps ◽

P. Garrido ◽

N. Viñolas ◽

J. Barcelo ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Single Agent ◽

Small Cell Lung ◽

Cancer Group ◽

Download Full-text

Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: A phase II trial

Lung Cancer ◽

10.1016/j.lungcan.2007.06.003 ◽

2007 ◽

Vol 58 (2) ◽

pp. 238-245 ◽

Author(s):

C. Pallarés ◽

J. Capdevila ◽

A. Paredes ◽

N. Farré ◽

J.P. Ciria ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Induction Chemotherapy ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell Lung ◽

Concurrent Radiotherapy ◽

Download Full-text

P-542 Carboplatin (C) and docetaxel (D) in the second-line treatment of non-small cell lung cancer (NSCLC) patients pretreated with platinum-based regimens. A Phase II trial

Lung Cancer ◽

10.1016/s0169-5002(05)81035-9 ◽

2005 ◽

Vol 49 ◽

pp. S260

Author(s):

G. Numico ◽

L. Buffoni ◽

V. Dongiovanni ◽

M. Schena ◽

C. Fissore ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Trial ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

Download Full-text